Chiara Della Bella

Dr. Chiara Della Bella

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2015 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
GEGiacomo Emmi
Giacomo Emmi
ESElena Silvestri
Elena Silvestri
DSDanilo Squatrito
Danilo Squatrito
Amedeo AmedeiAmedeo Amedei
Amedeo Amedei
Elena NiccolaiElena Niccolai
Elena Niccolai
DPDomenico Prisco
Domenico Prisco
In recent years, the relationship between inflammation and thrombosis has been deeply investigated and it is now clear that immune and coagulation systems are functionally interconnected. Inflammation-induced thrombosis is by now considered a feature not only of autoimmune rheumatic diseases, but also of systemic vasculitides such as Behçet’s syndrome, ANCA-associated vasculitis or giant cells arteritis, especially during active disease. These findings have important consequences in terms of management and treatment. Indeed, Behçet’syndrome requires immunosuppressive agents for vascular involvement rather than anticoagulation or antiplatelet therapy, and it is conceivable that also in ANCA-associated vasculitis or large vessel-vasculitis an aggressive anti-inflammatory treatment during active disease could reduce the risk of thrombotic events in early stages. In this review we discuss thrombosis in vasculitides, especially in Behçet’s syndrome, ANCA-associated vasculitis and large-vessel vasculitis, and provide pathogenetic and clinical clues for the different specialists involved in the care of these patients.

5 October 2012 in Internal and Emergency Medicine
Verified
Journal Article
Closed access
PDF file
Amedeo AmedeiAmedeo Amedei
Amedeo Amedei
FMFabio Munari
Fabio Munari
CBChiara Della Bella
Chiara Della Bella
ENElena Niccolai
Elena Niccolai
MBMarisa Benagiano
Marisa Benagiano
MDMario Milco D'Elios
Mario Milco D'Elios

3 May 2013 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
Amedeo AmedeiAmedeo Amedei
Amedeo Amedei
ENElena Niccolai
Elena Niccolai
MBMarisa Benagiano
Marisa Benagiano
CBChiara Della Bella
Chiara Della Bella
FCFabio Cianchi
Fabio Cianchi
MDMario Milco D'Elios
Mario Milco D'Elios

12 October 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
MPMatteo Pagliari
Matteo Pagliari
FMFabio Munari
Fabio Munari
MTMarta Toffoletto
Marta Toffoletto
SLSilvia Lonardi
Silvia Lonardi
FCFrancesco Chemello
Francesco Chemello
SCStefano Cagnin
Stefano Cagnin
Helicobacter pylori (Hp) is a Gram-negative bacterium that infects the human gastric mucosa, leading to chronic inflammation. If not eradicated with antibiotic treatment, the bacterium persists in the human stomach for decades increasing the risk to develop chronic gastritis, gastroduodenal ulcer and gastric adenocarcinoma. The life-long persistence of Hp in the human stomach suggests that the host response fails to clear the infection. It has been recently shown that during Hp infection phagocytic cells promote high Hp loads rather than contributing to bacterial clearance. Within these cells Hp survives in “megasomes”, large structures arising from homotypic fusion of phagosomes, but the mechanism that Hp employs to avoid phagocytic killing is not completely understood. Here we show that Hp infection induces the down-regulation of specific miRNAs involved in the regulation of transcripts codifying for inflammatory proteins. miR-4270 targets the most up-regulated gene: the immune receptor CD300E, whose expression is strictly dependent on Hp infection. CD300E engagement enhances the pro-inflammatory potential of macrophages, but in parallel it affects their ability to express and expose MHC class II molecules on the plasma membrane, without altering phagocytosis. This effect compromises the possibility for effector T cells to recognize and activate the killing potential of macrophages, that, in turn would become a survival niche for the bacterium. Taken together, our data add another piece to the complicate puzzle represented by the long-life coexistence between Hp and the human host and contribute with new insights towards understanding the regulation and function of the immune receptor CD300E.

1 December 2014 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
FMFabio Munari
Fabio Munari
Matteo FassanMatteo Fassan
Matteo Fassan
NCNagaja Capitani
Nagaja Capitani
Gaia CodoloGaia Codolo
Gaia Codolo
MVMarian Vila-Caballer
Marian Vila-Caballer
MBMarina De Bernard
Marina De Bernard
BAFF is a crucial cytokine that affects the activity of both innate and adaptive immune cells. It promotes the expansion of Th17 cells in autoimmune disorders. With this study, we investigated the BAFF/Th17 responses in Helicobacter pylori–induced gastritis in humans. Our results show that the mucosa from Helicobacter+ patients with chronic gastritis is enriched in IL-17 and BAFF, whereas the two cytokines are weakly expressed in Helicobacter− patients with chronic gastritis; moreover, the expression of both BAFF and IL-17 decreases after bacteria eradication. We demonstrate that BAFF accumulates in macrophages in vivo and that it is produced by monocyte-derived macrophages in vitro, after Helicobacter stimulation. Application of BAFF on monocytes triggers the accumulation of reactive oxygen species that are crucial for the release of pro-Th17 cytokines, such as IL-23, IL-1β, and TGF-β. Moreover, BAFF directly promotes the differentiation of Th17 cells. In conclusion, our results support the notion that an axis BAFF/Th17 exists in chronic gastritis of Helicobacter+ patients and that its presence strictly depends on the bacterium. Moreover, we demonstrated that BAFF is able to drive Th17 responses both indirectly, by creating a pro-Th17 cytokine milieu through the involvement of innate immune cells, and directly, via the differentiation of T cells toward the specific profile. The results obtained in this study are of great interest for Helicobacter-related diseases and the development of novel therapeutic strategies based on the inhibition of the BAFF/IL-17 response.

2 August 2011 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
MDMario Milco D'Elios
Mario Milco D'Elios
MBMarisa Benagiano
Marisa Benagiano
CBChiara Della Bella
Chiara Della Bella
AAAmedeo Amedei
Amedeo Amedei
T-cell responses are crucial for the outcome of any infection. The type of effector T-cell reaction is determined by a complex interaction of antigen-presenting cells with naive T cells and involves genetic and environmental factors, including the type of antigen, cytokines, chemokines, co-stimulatory molecules, and signalling cascades. The decision for the immune response to go in a certain direction is based not on one signal alone, but rather on many different elements acting both synergistically and antagonistically, and through feedback loops leading to activation or inhibition of T cells. In the course of evolution different types of T cells have developed, such as T helper 1 (Th1) cells, which protect against intracellular bacteria; Th2 cells, which play a role against parasites; and Th17 cells, which face extracellular bacteria and fungi